FP7Реинтеграция2010–2013

LOCUS COERULEUS-PAIN · ROLE OF LOCUS COERULEUS IN NEUROPATHIC PAIN

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2010-09-01 → 2013-08-31
Финансиране от ЕС
45 000 €
Участници
1
Схема
MC-ERG

Линиите свързват координатора с партньорите.

Накратко на български

Ролята на ядрото locus coeruleus в мозъка се анализира, за да се разбере как то влияе върху депресията и тревожността при хронична болка. Познаването на тези процеси помага за подобряване на диагностиката и лечението на пациенти с подобни състояния.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

ROLE OF LOCUS COERULEUS IN NEUROPATHIC PAIN

In normal circumstances, pain sensation signals tissue injury that could compromise the organism's survival and its welfare. In this sense, pain experience is composed of a sensory dimension, which includes the perception of location, quality, and intensity of a noxious stimulus, as well as an emotional dimension that processes the unpleasantness of the noxious stimulus. However, maintained painful states (chronic pain) may derive in pathological conditions with emotional, affective, and social implications. Indeed, many epidemiological studies have showed a deep relationship between the intensity of unpleasantness sensation and secondary emotions associated such as suffering and stress. This situation after a period of time may derive in psychiatric disorders, being the most common depression and anxiety. Once this happens, it enters in a vicious circle in which the worsening of affective sphere aggravates the pain perception and vice versa, worsening the patient’s prognosis. The knowledge of the underlying bases of these processes would help to develop new approaches to improve the diagnosis and treatment of chronic pain patients. In chronic pain, action potentials fire at a higher rate in nociceptors, which carry pain information to several brain areas. Thus, mood disorders may be the result of functionally impairment of neural substrates that affect pain, emotion, reward and/or motivation processing. To study the substrates that might impinge on these different circuits, we explored the role of the noradrenergic nucleus locus coeruleus (LC) to test the hypothesis that altered LC function may promote depressive and anxiogenic behavior in chronic pain. The LC is a relevant structure in both ascending and descending pain transmission. As the primary source of noradrenaline to the prefrontal cortex, the LC is regarded as part of the central “stress circuitry” involved in the pathophysiology of depression and anxiety disorders. With this aim, we have investigated the function of LC nucleus in a peripheral model of neuropathic pain (the chronic constriction injury (CCI)). This is an animal model that mimics most of the symptoms seen in clinical setting such as allodynia (pain due to a stimulus which does not normally provoke pain) and hyperalgesia (increased sensitivity to pain). At early stages of neuropathy development, the sensory dimension of pain was measured by testing the pain threshold, which decreased consistently from day 2 after inducing pain. We also explored the aversiveness of painful experiences with the place escape/avoidance test. This test permits the aversive nature of a noxious stimulus to be assessed on the basis of avoiding a preferred location (non anxiogenic area) where the stimulus is delivered. Accordingly, the pain group at early stage (1 week after injury) showed a higher preference for the anxiogenic area than the control group, showing that aversion to a painful experience increase in neuropathic rats. Strikingly, this preference was completely abolished in long-term neuropathic rats (4 weeks after injury). Furthermore, long-term neuropathic rats spent a substantially longer time in the non anxiogenic area area compared with control or short-term neuropathic rats, despite both pain groups having a similar sensorial pain threshold. This shows that anxiety is more significant than experiencing emotional pain in long-term neuropathic rats. Further studies showed that long-term neuropathic pain resulted in an inability to cope with stressful situations, provoking depressive and anxiogenic-like behaviors. This suggests that long-term chronic pain leads to emotional disorders that are more relevant than the intrinsic suffering caused by a painful stimulation. Regarding LC neurons, its tonic (spontaneous) function was not modified in spite of pain hypersensitivity was already present at early stages (1 week after injury). Indeed, no changes were observed in the neuronal tonic activity, alpha2-adrenoreceptors sensitivity and expression, G protein and RGS levels, and noradrenaline release in LC and prefrontal cortex. Although the tonic activity of LC was not modified in this early staged of CCI, phasic LC discharge upon nociceptive mechanical and electrical stimulations in the ipsilateral paw was alredy altered. However, long-term neuropathic pain temporally coincided with marked tonic (spontaneous) modifications of noradrenergic LC neurons. Indeed, we found an altered expression of tyrosine hydroxylase, noradrenaline transporter and alpha2-adrenoreceptors proteins that influenced on neuronal firing activity and noradrenaline release. Interestingly, similar changes in tyrosine hydroxylase, noradrenaline transporter and alpha2-adrenoreceptors levels in the LC have been described in animal models of depression and in post-mortem brain tissue of depressed individuals. In addition, nerve-injured rats showed an exacerbated phasic response upon nociceptive stimulation one month after the surgery. On the other hand, the treatment (one week) with desipramine (noradrenaline reuptake inhibitor) or duloxetine (serotonin and noradrenaline reuptake inhibitor) at the same time of CCI surgery prevented the alterations on phasic LC activity in parallel with their behavioural analgesic and antidepressant effects. When painful stimulus reaches the LC, noradrenergic neurons are activated, promoting noradrenaline release in both the LC and terminal areas like the spinal cord, contributing to the normal control of pain perception. However, as a consequence of spontaneous or evoked pain in chronic pain conditions, the LC might constantly receive nociceptive inputs, increasing noradrenaline requirements as well as leading to secondary homeostatic compensations that may cause the mood disorders in CCI animals. Therefore, the present study presents biological data to support the use of these noradrenaline reuptake inhibitors (antidepressants) to treat pain and its long-term consequences (mood disorders).

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The locus coeruleus, the main source of noradrenaline in the central nervous system, is a crucial step in both the descending and ascending pain modulatory systems which are compromised in neuropathic pain. Neuropathic pain is a chronic pathological condition arising from damage in the nervous system and that does not respond successfully to conventional analgesics. In fact, the first-line treatment approaches for neuropathic pain belong to drugs that modulate the activity of the locus coeruleus. In spite of this, LC role in neuropathic pain remains unknown. Locus coeruleus neuronal activity is modulated, among others, by G-protein-coupled receptors, α2-adrenoceptors presynaptically located. Indeed, the activation of these autoreceptors by noradrenaline circulating in the milieu active G protein-activated inwardly rectifying K+ channels (GIRK), hyperpolarizing the cell and inhibiting the release of the own neurotransmitter at LC level and projecting areas such as the spinal cord. This is a physiological feedback mechanism that control noradrenaline extracellular levels and consequently pain threshold. Thus, α2-adrenoceptors and GIRK channels seems to be a significant player in the locus coeruleus action potential frequency and therefore in the noradrenaline synaptic concentration. Thus, we suggest that they will play an essential role in ascending and descending pain transmission involved in neuropathic pain and that the knowledge of physiological processes responsible for their contribution to pain threshold will help to the design of a new line of anti-neuropathic drugs. We will tackle the project by implementing a broad range of techniques, from single-cell electrophysiology to whole-animal behavioural studies, and by correlating the results obtained by different techniques throughout the project.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз